. 2022 Jan 20;10(2):151. doi: 10.3390/vaccines10020151

Table 1.

Patient characteristic.

Characteristic	Category	Total n = 66 (%)	Seropositive n = 56 (%)	Seronegative n = 10 (%)	p Value
Gender ^a	Male	27 (41)	23 (41.1)	4 (40)	1.0
Gender ^a	Female	39 (59)	33 (58.9)	6 (60)	1.0
Age ^b			31 (18–49)	33.7 (21–53)	0.34
No. of doses ^a	One	32 (48)	23 (41.1)	9 (90)	0.005
No. of doses ^a	Two	34 (52)	33 (58.9)	1 (10)	0.005
Hemoglobinopathy ^a	TDT	51 (77)	43 (76.8)	8 (80)	1.0
Hemoglobinopathy ^a	SCD	15 (23)	13 (23.2)	2 (20)	1.0
Splenectomy ^a	Yes	31 (47)	25 (44.6)	6 (60)	0.5
Splenectomy ^a	No	35 (53)	31 (55.4)	4 (40)	0.5
Hydroxyurea ^a	Yes	17 (26)	15 (26.8)	2 (20)	1.0
Hydroxyurea ^a	No	49 (74)	41 (73.2)	8 (80)	1.0
Hyperferritinemia (>1000 μg/mL) ^a	Yes	54 (82)	45 (80.4)	9 (90)	0.7
Hyperferritinemia (>1000 μg/mL) ^a	No	12 (18)	11 (19.6)	1 (10)	0.7
History of COVID-19 ^a; Anti-N positive	Yes	31 (47)	31 (55.4)	0 (0)	0.001
History of COVID-19 ^a; Anti-N positive	No	35 (53)	25 (44.6)	10 (100)	0.001

^an (column percentage); ^b Mean (range). TDT = transfusion-dependent thalassemia, SCD = sickle cell disease.